Page 173 - Clinical Immunology_ Principles and Practice ( PDFDrive )
P. 173
CHaPTEr 9 Cytokines and Cytokine Receptors 155
84. Heinhuis B, Netea MG, van den Berg WB, et al. Interleukin-32: a 87. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of
predominantly intracellular proinflammatory mediator that controls cell canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med
activation and cell death. Cytokine 2012;60:321–7. 2012;367:2396–406.
85. Kim S. Interleukin-32 in inflammatory autoimmune diseases. Immune 88. Tran AP, Edelman J. Interleukin-1 inhibition by anakinra in refractory
Netw 2014;14:123–7. chronic tophaceous gout. Int J Rheum Dis 2011;14:e33–7.
86. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in 89. Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann
rheumatoid arthritis and the risk of serious infections and malignancies: N Y Acad Sci 2009;1182:111–23.
systematic review and meta-analysis of rare harmful effects in 90. Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med
randomized controlled trials. JAMA 2006;295:2275–85. 2013;368:1528–35.
